EGFR and glioblastoma: Thus, preclinical experiments suggest osimertinib was unable to significantly alter metabolic activity and growth properties in GBM, while intracranial EGFR-mutated NSCLC tumors showed both reduced 18F-FDG uptake and improved outcomes.